John Minna, M.D.
Professor & Director

Stanford University, Stanford, CA A.B. 1963 Psychology Stanford Medical School, Stanford, CA M.D. 1967 Medicine Massachusetts General Hospital, Boston, MA 1967-1969 Internal Medicine National Institutes of Health, Bethesda, MD 1969-1973 Genetics A. Positions and Honors. 1963-1967 Predoctoral Trainee PHS, Dept of Genetics, Stanford Medical School (Dr. L. Herzenberg) 1967-1969 Internship and Residency, Dept of Medicine, Massachusetts General Hosp, Boston, MA 1969-1973 Res Assoc, Lab. of Biochemical Genetics (LBG), NHLBI, NIH (Dr. Marshall Nirenberg) 1973-1975 Head, Section on Somatic Cell Genetics, LBG, NHLBI, NIH 1974-1991 Attending Physician, Clinical Center, NIH 1975-1981 Chief, NCI-VA Medical Oncology Branch, Clinical Oncology Program, DCT, NCI, NIH 1981-1991 Chief, NCI-Navy Medical Oncology Branch, COP, DCT, NCI, NIH 1981-1991 Prof of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 1969-1991 United States Public Health Service (PHS); Captain (06); Retired 1991 1991-Pres. Prof of Medicine & Pharmacology, UT Southwestern Medical Center Dallas (UTSWMC) 1991-1995 Director, Harold C. Simmons Cancer Center, UTSWMC, Lisa K. Simmon Distinguished Chair in Comprehensive Oncology, Chief, Division of Medical Oncology/Hematology 1995-Pres. Director, Hamon Center for Therapeutic Oncology Research and W.A. "Tex" & Deborah Moncrief Jr. Center for Cancer Genetics, UTSWMC, Sarah M. & Charles E. Seay Distinguished Chair in Cancer Research, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology Honors PHS: Commendation Medal (1979), Meritorious Service Medical (1986), Unit Commendation Medal (1991); Rosenthal Prize for Cancer Research (1984); Milken Foundation Award for Scientific Excellence in Clinical Research (1989); Chester Stock Award, Memorial Sloan-Kettering Cancer Center (1992); Bristol Myers Squibb Award for Lung Cancer Research (1997); Moran Award Univ. Michigan (2000), NCI SPORE Program Award for Leadership (2003), Ochsner Award Smoking Related Research (2004), ASCO Scientific Achievement Award (2005), ASCO Lifetime Achievement Award (2007) B. Selected peer-reviewed publications (2006-2007). Sato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., Ramirez, R. D., Sunaga, N., Gazdar, A. F., Shay, J. W., and Minna, J. D. Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Res, 66: 2116-2128, 2006. Zhou, B. B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., Yang, G., Li, Y., Yao, W., Vaddi, K., Gazdar, A. F., Friedman, S. M., Jablons, D. M., Newton, R. C., Fridman, J. S., Minna, J. D., and Scherle, P. A. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell, 10: 39-50, 2006. Deng, W. G., Kawashima, H., Wu, G., Jayachandran, G., Xu, K., Minna, J. D., Roth, J. A., and Ji, L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res, 67: 709-717, 2007. Lam, D. C., Girard, L., Ramirez, R., Chau, W. S., Suen, W. S., Sheridan, S., Tin, V. P., Chung, L. P., Wong, M. P., Shay, J. W., Gazdar, A. F., Lam, W. K., and Minna, J. D. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res, 67: 4638-4647, 2007. Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., Xie, X. J., and White, M. A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature, 446: 815-819, 2007.

Medical School

Stanford University Medical Center (1967)

Internship

Massachusetts General Hospital (1968), Medicine

Residency

Massachusetts General Hospital (1969), Medicine

Fellowship

National Institutes of Health (1973), Biochemical Genetics

• Breast Cancer
• Genome wide mRNA, protein, and DNA analysis
• Lung Cancer
• Molecular biomarkers of response to cancer therapy
• Molecular pathogenesis of human cancer

Featured Publications

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.

Gong K, Guo G, Beckley NA, Yang X, Zhang Y, Gerber DE, Minna JD, Burma S, Zhao D, Akbay EA, Habib AA, Nat Commun 2021 12 12 1 7014

Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.

Rolfo C, Meshulami N, Russo A, Krammer F, Garcia-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA, Minna JD, Hirsch FR, J Thorac Oncol 2021 Nov

Phosphatidylserine receptors enhance SARS-CoV-2 infection.

Bohan D, Van Ert H, Ruggio N, Rogers KJ, Badreddine M, Aguilar Briseño JA, Elliff JM, Rojas Chavez RA, Gao B, Stokowy T, Christakou E, Kursula P, Micklem D, Gausdal G, Haim H, Minna J, Lorens JB, Maury W, PLoS Pathog 2021 Nov 17 11 e1009743

ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer.

Pozo K, Kollipara RK, Kelenis DP, Rodarte KE, Ullrich MS, Zhang X, Minna JD, Johnson JE, iScience 2021 Sep 24 9 102953

Dual targeting of CTLA-4 and CD47 on T_reg cells promotes immunity against solid tumors.

Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, Cai Y, Minna JD, Fu YX, Sci Transl Med 2021 08 13 605

Lentiviral-driven discovery of cancer drug resistance mutations.

Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R, Cancer Res 2021 Jul

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.

Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA, J Thorac Oncol 2021 Jul

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA, Cancer Cell 2021 Mar 39 3 346-360.e7

SH3BP4 promotes neuropilin-1 and a5-integrin endocytosis and is inhibited by Akt.

Burckhardt CJ, Minna JD, Danuser G, Dev Cell 2021 Mar

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.

Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, Li Y, Zhang YA, Deb D, Stastny V, Pozo K, Kuo CS, Jia G, Yang C, Zou W, Alomar A, Huffman K, Papari-Zareei M, Yang L, Drapkin B, Akbay EA, Shames DS, Wistuba II, Wang T, Johnson JE, Xiao G, DeBerardinis RJ, Minna JD, Xie Y, Gazdar AF, Commun Biol 2021 Mar 4 1 314

• ASCO Award
  Statesman (2007)
• ASCO Award
  Lifetime Scientific Achievement (2005)
• Ochsner Award
  Award for Smoking Related Research (2004)
• Bristol Myers Squibb Award
  Award for Lung Cancer Research (1997)
• Rosenthal Prize
  Prize for Cancer Research (1984)

• American Association for Cancer Research (AACR)
• American Society of Clinical Oncology (ASCO)
• ASBMB, ASCI, AFCR, ASH, IASLC
• Association of American Physicians (AAP)
• Fellow American College of Physicians (FACP)